[
    {
        "gene_name":"GNAS",
        "genomic_position":"20:57427769-57486247(+)",
        "cds_mutation":"R201H",
        "aa_mutation":"p.R201H",
        "disease":"Thyroid Gland Follicular Carcinoma",
        "therapy_rank":4,
        "response_to_drug":"Sensitivity",
        "therapies":"Radioactive Iodine",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:26788326"
    },
    {
        "gene_name":"BRAF",
        "genomic_position":"7:140434279-140624564(-)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"thyroid | carcinoma | NS",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"Pertuzumab,Vemurafenib",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:29320312"
    },
    {
        "gene_name":"BRAF",
        "genomic_position":"7:140434279-140624564(-)",
        "cds_mutation":"c.1799T>A",
        "aa_mutation":"p.V600E",
        "disease":"Thyroid Gland Anaplastic Carcinoma",
        "therapy_rank":2,
        "response_to_drug":"Sensitivity",
        "therapies":"Pertuzumab,Vemurafenib",
        "description":null,
        "rs_value":113488022.0,
        "pmid":"PubMed:29320312"
    },
    {
        "gene_name":"BRAF",
        "genomic_position":"7:140434279-140624564(-)",
        "cds_mutation":"c.1799T>A",
        "aa_mutation":"p.V600E",
        "disease":"thyroid | carcinoma | NS",
        "therapy_rank":2,
        "response_to_drug":"Sensitivity",
        "therapies":"Pertuzumab,Vemurafenib",
        "description":null,
        "rs_value":113488022.0,
        "pmid":"PubMed:29320312"
    },
    {
        "gene_name":"BRAF",
        "genomic_position":"7:140434279-140624564(-)",
        "cds_mutation":"V600E\/K",
        "aa_mutation":"p.V600E\/K",
        "disease":"thyroid | carcinoma | anaplastic carcinoma",
        "therapy_rank":2,
        "response_to_drug":"Sensitivity",
        "therapies":"Pertuzumab,Vemurafenib",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:29320312"
    },
    {
        "gene_name":"BRAF",
        "genomic_position":"7:140434279-140624564(-)",
        "cds_mutation":"c.1799T>A",
        "aa_mutation":"p.V600E",
        "disease":"thyroid | carcinoma | anaplastic carcinoma",
        "therapy_rank":2,
        "response_to_drug":"Sensitivity",
        "therapies":"Pertuzumab,Vemurafenib",
        "description":null,
        "rs_value":113488022.0,
        "pmid":"PubMed:29320312"
    },
    {
        "gene_name":"BRAF",
        "genomic_position":"7:140434279-140624564(-)",
        "cds_mutation":"c.1799T>A",
        "aa_mutation":"p.V600E",
        "disease":"thyroid | carcinoma | papillary carcinoma",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Pertuzumab,Vemurafenib",
        "description":null,
        "rs_value":113488022.0,
        "pmid":"PubMed:29320312"
    },
    {
        "gene_name":"BRAF",
        "genomic_position":"7:140434279-140624564(-)",
        "cds_mutation":"c.1799T>A",
        "aa_mutation":"p.V600E",
        "disease":"Thyroid Gland Papillary Carcinoma",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Pertuzumab,Vemurafenib",
        "description":null,
        "rs_value":113488022.0,
        "pmid":"PubMed:29320312"
    },
    {
        "gene_name":"BRAF",
        "genomic_position":"7:140434279-140624564(-)",
        "cds_mutation":"c.1799T>A",
        "aa_mutation":"p.V600E",
        "disease":"Thyroid Gland Anaplastic Carcinoma",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Pertuzumab,Vemurafenib",
        "description":null,
        "rs_value":113488022.0,
        "pmid":"PubMed:29320312"
    },
    {
        "gene_name":"BRAF",
        "genomic_position":"7:140434279-140624564(-)",
        "cds_mutation":"V600E\/M",
        "aa_mutation":"p.V600E\/M",
        "disease":"thyroid | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Pertuzumab,Vemurafenib",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:29320312"
    },
    {
        "gene_name":"BRAF",
        "genomic_position":"7:140434279-140624564(-)",
        "cds_mutation":"c.1799T>A",
        "aa_mutation":"p.V600E",
        "disease":"thyroid | carcinoma | anaplastic carcinoma",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Pertuzumab,Vemurafenib",
        "description":null,
        "rs_value":113488022.0,
        "pmid":"PubMed:29320312"
    },
    {
        "gene_name":"BRAF",
        "genomic_position":"7:140434279-140624564(-)",
        "cds_mutation":"c.1798delinsTACA",
        "aa_mutation":"p.V600",
        "disease":"thyroid | carcinoma | anaplastic carcinoma",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Pertuzumab,Vemurafenib",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:29320312"
    },
    {
        "gene_name":"BRAF",
        "genomic_position":"7:140434279-140624564(-)",
        "cds_mutation":"c.1799T>A",
        "aa_mutation":"p.V600E",
        "disease":"thyroid | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Pertuzumab,Vemurafenib",
        "description":null,
        "rs_value":113488022.0,
        "pmid":"PubMed:29320312"
    },
    {
        "gene_name":"BRAF",
        "genomic_position":"7:140434279-140624564(-)",
        "cds_mutation":"c.1799T>A",
        "aa_mutation":"p.V600E",
        "disease":"Thyroid Gland Papillary Carcinoma",
        "therapy_rank":4,
        "response_to_drug":"Sensitivity",
        "therapies":"Pertuzumab,Vemurafenib",
        "description":null,
        "rs_value":113488022.0,
        "pmid":"PubMed:29320312"
    },
    {
        "gene_name":"BRAF",
        "genomic_position":"7:140434279-140624564(-)",
        "cds_mutation":"c.1799T>A",
        "aa_mutation":"p.V600E",
        "disease":"Thyroid Gland Anaplastic Carcinoma",
        "therapy_rank":4,
        "response_to_drug":"Sensitivity",
        "therapies":"Pertuzumab,Vemurafenib",
        "description":null,
        "rs_value":113488022.0,
        "pmid":"PubMed:29320312"
    },
    {
        "gene_name":"ALK",
        "genomic_position":"2:29415640-30144432(-)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"thyroid | carcinoma | anaplastic carcinoma",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Crizotinib",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:24687827"
    },
    {
        "gene_name":"ALK",
        "genomic_position":"2:29415640-30144432(-)",
        "cds_mutation":"Fusion",
        "aa_mutation":"Fusion",
        "disease":"Thyroid Gland Anaplastic Carcinoma",
        "therapy_rank":4,
        "response_to_drug":"Sensitivity",
        "therapies":"Crizotinib",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:24687827"
    },
    {
        "gene_name":"HRAS",
        "genomic_position":"11:532243-535550(-)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"thyroid | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Tipifarnib",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT02383927"
    },
    {
        "gene_name":"KRAS",
        "genomic_position":"12:25362365-25403737(-)",
        "cds_mutation":"G12_or_HRAS_G13_or_HRAS_Q61_or_KRAS_G12_or_KRAS_G13_or_KRAS_Q61_or_NRAS_G12_or_NRAS_G13_or_NRAS_Q61",
        "aa_mutation":"p.G12_or_HRAS_G13_or_HRAS_Q61_or_KRAS_G12_or_KRAS_G13_or_KRAS_Q61_or_NRAS_G12_or_NRAS_G13_or_NRAS_Q61",
        "disease":"thyroid | carcinoma | NS",
        "therapy_rank":2,
        "response_to_drug":"Sensitivity",
        "therapies":"Radioiodine + Trametinib",
        "description":null,
        "rs_value":null,
        "pmid":"DOI:NCT02152995"
    },
    {
        "gene_name":"NRAS",
        "genomic_position":"1:115247090-115259515(-)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"thyroid | carcinoma | NS",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"Radioiodine + Selumetinib",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT01843062"
    },
    {
        "gene_name":"NRAS",
        "genomic_position":"1:115247090-115259515(-)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"thyroid | carcinoma | NS",
        "therapy_rank":2,
        "response_to_drug":"Sensitivity",
        "therapies":"Radioiodine + Selumetinib",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT01843062"
    },
    {
        "gene_name":"NRAS",
        "genomic_position":"1:115247090-115259515(-)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"thyroid | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Radioiodine + Selumetinib",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT01843062"
    },
    {
        "gene_name":"TP53",
        "genomic_position":"17:7571720-7590856(-)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"thyroid | carcinoma | anaplastic carcinoma",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Cisplatin + Crolibulin",
        "description":null,
        "rs_value":null,
        "pmid":"DOI:NCT01240590"
    }
]